Discover details of the KEYNOTE-045, which recently resulted in the recommendation for the use of pembrolizumab within the cancer drugs fund as an option for the treatment of locally advanced or metastatic urothelial carcinoma in adults who have had platinum-containing chemotherapy.
Pembrolizumab becomes the first and only immunotherapy to be recommended by NICE for urothelial carcinoma patients
Pembrolizumab has become the first and only immunotherapy that NICE has recommended for urothelial carcinoma patients who have failed on platinum-containing chemotherapy.
Discover the signs, symptoms of colorectal cancer as well as the latest advancements in the field in this video with Jade Parker, Oncology Central Editor.
The world’s third most common cancer, colorectal cancer (CRC) is responsible for an estimated 694,000…
One definition of rare cancers is that with an incidence of less than six cases…
Merck & Co. have signed a definitive agreement to acquire Viralytics for approximately $394 million, the companies has announced.
AstraZeneca’s novel immunotherapy for non-small cell lung cancer has been authorized for use by the FDA.
Discover details of Bristol-Myer Squibbs latest immuno-oncology drug deal, DiaCarta’s funding into its diagnostic platform and Cancer Research UK’s pledge to invest £45 million into clinical trials.
Delve deeper into the promising PD-L1 research being published, in this patient perspective piece from Stage IV melanoma patient T.J. Sharpe.
This review summarizes the past decade of immunotherapy for non-small-cell lung cancer, gives an updated overview of trials in this field, and the context of future development in this exciting field.